First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Contro

First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Controlled, Phase III Study is a phase 3, randomised interventional study registered as NCT06616259 by Meng Qiu, with a registry enrolment figure of 452 participants, started 2024-09-26 and due to reach its primary completion in 2028-09-30. Interventions recorded: mCapOX plus Cetuximab; mFOLFOX6 plus Cetuximab. Conditions listed: Colorectal Cancer (CRC); Capecitabine; Cetuximab. Primary outcome: Progression free survival (PFS). Colorectal eligibility wording from the registry: "* Patients with histologically or cytologically confirmed RAS and BRAF wild-type, MSS/pMMR, metastatic left-sided colorectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.